Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Treasury Shares (2016 - 2025)

Ironwood Pharmaceuticals' Treasury Shares history spans 15 years, with the latest figure at $5.4 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 2695.4% to $5.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.4 million, a 2695.4% increase, with the full-year FY2025 number at $5.4 million, up 2695.4% from a year prior.
  • Treasury Shares hit $5.4 million in Q4 2025 for Ironwood Pharmaceuticals, up from $194488.0 in the prior quarter.
  • Over the last five years, Treasury Shares for IRWD hit a ceiling of $5.4 million in Q4 2025 and a floor of $194488.0 in Q4 2024.
  • Historically, Treasury Shares has averaged $2.5 million across 5 years, with a median of $1.7 million in 2023.
  • Biggest five-year swings in Treasury Shares: plummeted 88.24% in 2024 and later skyrocketed 2695.4% in 2025.
  • Tracing IRWD's Treasury Shares over 5 years: stood at $3.9 million in 2021, then tumbled by 69.75% to $1.2 million in 2022, then soared by 41.45% to $1.7 million in 2023, then plummeted by 88.24% to $194488.0 in 2024, then skyrocketed by 2695.4% to $5.4 million in 2025.
  • Business Quant data shows Treasury Shares for IRWD at $5.4 million in Q4 2025, $194488.0 in Q4 2024, and $1.7 million in Q4 2023.